Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 1

Status

Completed 3

Sponsor Class

OTHER 119NIH 26NETWORK 20INDUSTRY 5OTHER_GOV 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Neoplasms, Germ Cell and Embryonal 1Hodgkin Disease 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Ifosfamide × Clear all
NCT02414685 2020-08-07

TIP

National Cancer Institute, Slovakia

Phase 2 Completed
19 enrolled

Neoplasms, Germ Cell and Embryonal

NCT00280878 2016-01-15

Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

Bayside Health

Phase 2 Completed
12 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT00163761 2016-01-08

Efficacy Study of Outpatient Therapy for Lymphoma

Bayside Health

Phase 2 Completed
90 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡